Updates are available Erratum dated 2018-01-01
Click to view Erratum: https://doi.org/10.1038/nrd.2017.267
-
Authors
Schwartz, Daniella M.
Kanno, Yuka
Villarino, Alejandro
Ward, Michael
Gadina, Massimo
O'Shea, John J.
- License Information
-
More Information
Article History
First Online: 6 November 2017
Change Date: 28 December 2017
Change Type: Correction
Change Details: In the version of this article that was originally published, there was an error in Figure 3 on page 847. In this figure, the structure attributed to the compound BMS-986165 is incorrect and the correct structure for this compound has not yet been disclosed. This error has now been corrected in the online version of the article, and the structure of SAR-20347 has been added instead. We apologize for any inconvenience that this error may have caused.
Competing interests
: J.O'S. declares that he and the US Government receive royalties based on patents related to the targeting of Janus kinases. J.O'S., M.G. and the US Government have had longstanding Cooperative Research and Development Agreements with Pfizer, which produces tofacitinib, a Janus kinase inhibitor.
